Covid-19 (Temas de Saúde Pública)
M-A | Eficácia e efetividade das vacinas contra SARS-CoV-2.
6 Mai, 2022 | 17:36hEfficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis – Vaccines
M-A | Taxas de ataque secundário domiciliar de SARS-CoV-2 por variantes e status vacinal.
2 Mai, 2022 | 13:58h
Comentário no Twitter
This systematic review & meta-analysis found household #SARSCoV2 secondary attack rates increased over time and were higher for variants than prior reported estimates. Vaccination was associated with reduced transmission (more for Alpha vs Delta & Omicron) https://t.co/6vwW0u3vY7
— JAMA Network Open (@JAMANetworkOpen) April 28, 2022
Estudo observacional | Impacto das vacinas contra Covid-19 na saúde pública dos EUA.
29 Abr, 2022 | 15:13hPublic health impact of covid-19 vaccines in the US: observational study – The BMJ
Editorial: The benefits of large scale covid-19 vaccination – The BMJ
Comentário no Twitter (fio – clique para saber mais)
Paper and accompanying editorial https://t.co/uwqY0PqYsE
"Many more lives could have been saved……
this new study is another confidence booster for covid-19 vaccines." pic.twitter.com/o4FygrAX8T— Eric Topol (@EricTopol) April 27, 2022
Especialistas temem que os EUA padronizem o reforço anual de vacinas contra Covid sem dados suficientes.
29 Abr, 2022 | 15:11hExperts fear U.S. may default to annual Covid boosters without sufficient data – STAT
Comentário no Twitter
Vaccine experts are concerned the U.S. may be sleepwalking into a policy of recommending annual Covid-19 vaccine boosters — without having generated the evidence to show they are actually needed. https://t.co/3TiNZvP0HY
— STAT (@statnews) April 26, 2022
Sintomas persistentes de COVID-19 em estudo comunitário de 606.434 pessoas na Inglaterra.
27 Abr, 2022 | 16:41h
Comentário no Twitter
Thirty-eight percent of participants from a community-based study of symptoms following COVID-19 reported persistent symptoms that lasted 12 weeks or more, according to an article published in @NatureComms. https://t.co/sAEutdOkSS pic.twitter.com/oCyyXGIRbk
— Nature Portfolio (@NaturePortfolio) April 20, 2022
Covid-19: estudo mostra que somente 1/4 dos pacientes admitidos em hospital sentem-se completamente recuperados após 1 ano.
27 Abr, 2022 | 16:39hComentário convidado: Long COVID: systemic inflammation and obesity as therapeutic targets – The Lancet Respiratory Medicine
Comentário no Twitter (fio – clique para saber mais)
PHOSP-COVID study:
– 232 (29%) of 804 pts fully recovered at 1y
– Female sex, obesity, & IMV = less likely to feel fully recovered
– inflamm mediators📈in those w/ most severe physical, mental health, & cognitive impairmentsRead it here: https://t.co/rVZuVDo4xl
— The Lancet Respiratory Medicine (@LancetRespirMed) April 25, 2022
Estudo de coorte | Gravidade da COVID-19 e trajetória da morbidade da saúde mental em populações de pacientes de 6 nações.
27 Abr, 2022 | 16:35hComunicado de imprensa: Study suggests association between severe COVID-19 and long-term mental health outcomes 16 months after an illness – Lancet
Comentário: Lasting depression and anxiety can follow severe case of Covid – NBC News
Comentário no Twitter (fio – clique para saber mais)
In our study published in the @TheLancetPH, we found that a mild course of acute illness (never bedridden due to #COVID19) was associated with a persistently lower risk of adverse #mentalhealth outcomes. https://t.co/aHBQTaOi4K
Several factors might contribute to this pattern🔽
— COVIDMENT research project (@COVIDMENT) April 11, 2022
Reinfecções por SARS-CoV-2: visão geral da eficácia e duração da imunidade natural e híbrida.
27 Abr, 2022 | 15:40hEstudos relacionados: Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19 – JAMA Network Open E Comentários: COVID-19 infection granted patients strong and long-lasting protection from reinfection – Providence Health & Services E COVID-19 infection may offer similar immunity as vaccination – CIDRAP
OMS recomenda o nirmatrelvir-ritonavir para o tratamento da COVID-19 e pede para uma maior distribuição geográfica.
25 Abr, 2022 | 12:47hVer também:
A living WHO guideline on drugs for covid-19 – The BMJ
Therapeutics and COVID-19: living guideline – World Health Organization
Conteúdos relacionados:
Comentário no Twitter
🔥 Our latest @WHO living guidance on drugs for #COVID19, with new recommendations for nirmatrelvir-ritonavir & updated recommendation for remdesivir in non-severe illness.@bmj_latest: https://t.co/KuJjwzeTPV@WHO: https://t.co/n3iQx3pdmY@theMAGICapp: https://t.co/dA7YYzeAZ1 pic.twitter.com/LvAhJf70UY
— Arnav Agarwal (@ArnavAgarwalMD) April 21, 2022
Análise longitudinal de dados de 15 países | Rigor das políticas e saúde mental durante a pandemia de COVID-19.
25 Abr, 2022 | 12:39hComunicado de imprensa: Stricter COVID-19 measures associated with negative mental health effects and lower opinion of government’s pandemic response, new research suggests – The Lancet